Somatic Delivery of Catecholamines in the Striatum Attenuate Parkinsonian Symptoms and Widen the Therapeutic Window of Oral Sinemet in Rats

Lindner, Mark D.; Plone, Melissa A.; Mullins, Ted D.; Winn, Shelley R.; Chandonait, Susan E.; Stott, Jennifer A.; Blaney, Thomas J; Sherman, Sandy S.; Emerich, Dwaine F.

doi:10.1006/exnr.1997.6456

Cited by 21 publications

(3 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forelimb adduction was quantified by observing the rats for 5 min periods in a Plexiglas cylinder (20 cm diameter, 40 cm height). The cumulative time that each forepaw was adducted while the other paw was in contact with the floor or walls of the cage for postural support or locomotion was recorded (Lindner, 1990;Schallert et al, 1990;Lindner et al, 1995Lindner et al, , 1997b.…”

Section: Chronic Functional Assessmentsmentioning

confidence: 99%

Long-Lasting Functional Disabilities in Middle-Aged Rats with Small Cerebral Infarcts

et al. 2003

Self Cite

View full text Add to dashboard Cite

Recommendations from experts and recently established guidelines on how to improve the face and predictive validity of animal models of stroke have stressed the importance of using older animals and long-term behavioral-functional endpoints rather than relying almost exclusively on acute measures of infarct volume in young animals. The objective of the present study was to determine whether we could produce occlusions in older rats with an acceptable mortality rate and then detect reliable, long-lasting functional deficits. A reversible intraluminar suture middle cerebral artery occlusion (MCAO) procedure was used to produce small infarcts in middle-aged rats. This resulted in an acceptable mortality rate, and robust disabilities were detected in functional assays, although the degree of total tissue loss measured 90 d after MCAO was quite modest. Infarcted animals were functionally impaired relative to sham control animals even 90 d after the occlusions, and when animals were subgrouped based on amount of tissue loss, MCAO animals with only 4% tissue loss exhibited enduring neurological-behavioral impairments relative to sham-operated controls, and the functional impairments in the group with the largest infarcts (20% tissue loss) were more severe than the functional impairments in the rats with 4% tissue loss. These results suggest that this model, using reversible MCAO to produce small infarcts and long-lasting functional-behavioral deficits in older rats, may represent an advance in the relatively higher-throughput modeling of stroke and its recovery in rodents and may be useful in the development and characterization of future stroke therapies.

show abstract

Section: Chronic Functional Assessmentsmentioning

confidence: 99%

Long-Lasting Functional Disabilities in Middle-Aged Rats with Small Cerebral Infarcts

et al. 2003

Self Cite

View full text Add to dashboard Cite

show abstract

“…Macrocapsules as well as microcapsules have been applied in a variety of animal models in vivo, and the number of clinical trials is also increasing (Tables 1 and 2). Several investigators have reported alleviations of symptoms of experimental parkinsonism in rats by implanting different devices with dopamine-releasing cells (Aebischer et al, 1991;Lindner et al, 1997). In a monkey model of Huntington's diseases, CNTF released from encapsulated baby hamster kidney cells reduced the extent of striatal damage (Emerich et al, 1997).…”

Section: Animal Experiments and Clinical Trialsmentioning

confidence: 99%

Cell encapsulation technology as a therapeutic strategy for CNS malignancies

2001

View full text Add to dashboard Cite

Gene therapy using viral vectors has to date failed to reveal its definitive clinical usefulness. Cell encapsulation technology represents an alternative, nonviral approach for the delivery of biologically active compounds to tumors. This strategy involves the use of genetically engineered producer cells that secrete a protein with therapeutic potential. The cells are encapsulated in an immunoisolating material that makes them suitable for transplantation. The capsules, or bioreactors, permit the release of recombinant proteins that may assert their effects in the tumor microenvironment. During the last decades, there has been significant progress in the development of encapsulation technologies that comprise devices for both macro- and microencapsulation. The polysaccharide alginate is the most commonly used material for cell encapsulation and is well tolerated by various tissues. A wide spectrum of cells and tissues has been encapsulated and implanted, both in animals and humans, indicating the general applicability of this approach for both research and medical purposes, including CNS malignancies. Gliomas most frequently recur at the resection site. To provide local and sustained drug delivery, the bioreactors can be implanted in the brain parenchyma or in the ventricular system. The development of comprehensive analyses of geno- and phenotypic profiles of a tumor (genomics and proteomics) may provide new and important guidelines for choosing the optimal combination of bioreactors and recombinant proteins for therapeutic use.

show abstract

“…Several investigators have reported alleviations of symptoms of experimental parkinsonism in rats by implanting different devices with dopamine-releasing cells (Aebischer et al, 1991;Lindner et al, 1997). In a monkey model of Huntington's diseases, CNTF released from encapsulated baby hamster kidney cells reduced the extent of striatal damage .…”

Section: Animal Experiments and Clinical Trialsmentioning

confidence: 99%

Cell encapsulation technology as a therapeutic strategy for CNS malignancies

Visted¹

2001

Neuro-Oncology

View full text Add to dashboard Cite

Neuro-Oncology n J U LY 2 0 0 1 201 Gene therapy using viral vectors has to date failed to reveal its de nitive clinical usefulness. Cell encapsulation technology represents an alternative, nonviral approach for the delivery of biologically active compounds to tumors. This strategy involves the use of genetically engineered producer cells that secrete a protein with therapeutic potential. The cells are encapsulated in an immunoisolating material that makes them suitable for transplantation. The capsules, or bioreactors, permit the release of recombinant proteins that may assert their effects in the tumor microenvironment. During the last decades, there has been signi cant progress in the development of encapsulation technologies that comprise devices for both macro-and microencapsulation. The polysaccharide alginate is the most commonly used material for cell encapsulation and is well tolerated by various tissues. A wide spectrum of cells and tissues has been encapsulated and implanted, both in animals and humans, indicating the general applicability of this approach for both research and medical purposes, including CNS malignancies. Gliomas most frequently recur at the resection site. To provide local and sustained drug delivery, the bioreactors can be implanted in the brain parenchyma or in the ventricular system. The development of comprehensive analyses of geno-and phenotypic pro les of a tumor (genomics and proteomics) may provide new and important guidelines for choosing the optimal combination of bioreactors and recombinant proteins for therapeutic use. Neuro-Oncology 3, 201-210, 2001 (Posted to Neuro-Oncology [serial online], Doc. 00-064,

show abstract

Somatic Delivery of Catecholamines in the Striatum Attenuate Parkinsonian Symptoms and Widen the Therapeutic Window of Oral Sinemet in Rats

Cited by 21 publications

References 79 publications

Long-Lasting Functional Disabilities in Middle-Aged Rats with Small Cerebral Infarcts

Long-Lasting Functional Disabilities in Middle-Aged Rats with Small Cerebral Infarcts

Cell encapsulation technology as a therapeutic strategy for CNS malignancies

Cell encapsulation technology as a therapeutic strategy for CNS malignancies

Contact Info

Product

Resources

About